Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, T-Cell, Peripheral 7Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Leukemia, Myeloid, Acute 6Lymphoma, T-Cell, Cutaneous 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Lung Neoplasms 4Hodgkin Disease 4Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 3Urinary Bladder Neoplasms 3Sarcoma 3Neoplasms 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Immunoblastic Lymphadenopathy 3Fallopian Tube Neoplasms 3Burkitt Lymphoma 3Thyroid Neoplasms 2

Interventions

Dexamethasone 13Bortezomib 8Cyclophosphamide 6Lenalidomide 5pomalidomide 3isatuximab 3glucarpidase 3Kidney Transplantation 3Calcium Dobesilate 3Thalidomide 2Paclitaxel 2Gemcitabine 2Carboplatin 2Blood Specimen Collection 2Bendamustine Hydrochloride 2Azacitidine 2vinflunine 1veliparib 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1pembrolizumab 1osimertinib 1mirabegron 1melflufen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Insufficiency × belinostat × Clear all
NCT02679131 2019-11-20

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

Acrotech Biopharma Inc.

Phase 1 Terminated
18 enrolled
Other hematologic neoplasm

Recurrence, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡